Markus Renschler MD - 29 Feb 2024 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role: President and CEO, Director
Signature: /s/ David Gaiero, as attorney-in-fact for Markus Renschler, M.D.
Issuer symbol: N/A
Transactions as of: 29 Feb 2024
Net transactions value: +$35,004
Form type: 4
Filing time: 05 Mar 2024, 18:10:05 UTC
Previous filing: 14 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYT	Common Stock	Options Exercise	$21,306	+12,607	+1.2%	$1.69	1,094,820	29 Feb 2024	Direct
transaction	CYT	Common Stock	Options Exercise	$3,044	+2,537	+0.23%	$1.20	1,097,357	29 Feb 2024	Direct
transaction	CYT	Common Stock	Options Exercise	$10,654	+6,304	+0.57%	$1.69	1,103,661	04 Mar 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYT	Stock Option (Right to Buy)	Options Exercise	$0	-12,607	-5.3%	$0.000000	226,952	29 Feb 2024	Common Stock	12,607	$1.69	Direct	F1
transaction	CYT	Stock Option (Right to Buy)	Options Exercise	$0	-2,537	-100%	$0.000000^*	0	29 Feb 2024	Common Stock	2,537	$1.20	Direct
transaction	CYT	Stock Option (Right to Buy)	Options Exercise	$0	-6,304	-2.8%	$0.000000	220,648	04 Mar 2024	Common Stock	6,304	$1.69	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.